Navigation Links
Doctors, Biotech Leaders, and Policymakers Gather to Discuss Roadblocks to Innovation and Advancing the 21st Century Cures Initiative
Date:8/25/2014

Boston, MA (PRWEB) August 25, 2014

The Manhattan Institute (MI) and its Project FDA, in partnership with the Tufts Center for the Study of Drug Development, will host the first in a series of public discussions about the reforms necessary to accelerate patient access to life-saving treatments, lower the cost of developing and delivering better treatments, and maintain America’s place as the world leader in bio-innovation. Future events will take place in other leading biotech hubs, including San Francisco and San Diego, CA.

Dr. Andrew von Eschenbach, former FDA commissioner and chairman of MI's Project FDA, will convene key policymakers, patient advocates, academics, and industry experts on August 25 at the Tufts University School of Medicine for a series of panels. Panel topics will include Congress’ 21st Century Cures Initiative, building a better framework for approving new medicines, and using big data to support patient-centered innovation. Panel participants include Rep. Michael Burgess, (TX-26); Dr. Kenneth Kaitin, director and professor, Tufts Center for the Study of Drug Development; Dr. Phillip Sharp, Nobel laureate and professor, MIT; and Jeff Allen, PhD, executive director, Friends of Cancer Research.

Biotech leaders participating include Nick Leschly, president and CEO, Bluebird Bio; Alan Eisenberg, vice president, federal government relations, Celgene; Robert Popovian, senior director, advocacy & professional relations, Pfizer; and Ketan Paranjape, worldwide director of health and life sciences, Intel.

Paul Howard, senior fellow at MI and member of Project FDA, said, “The current drug development paradigm is breaking down – it’s just too expensive and time-consuming. The Manhattan Institute’s Project FDA is focused on helping regulators, companies, patient advocates, and policymakers create a more predictable, transparent, and efficient pathway for bringing safe and effective new therapies to patients.”

“My colleague Peter Huber’s new book, The Cure in the Code, outlines a roadmap for advancing medicine and drug regulation into the 21st Century. What we need to do now is move from vision to reality. Thankfully, Congress’s bipartisan 21st Century Cures Initiative is working to do just that,” Howard added.

The Manhattan Institute is a think tank whose mission is to develop and disseminate new ideas that foster greater economic choice and individual responsibility. Under the leadership of Dr. Andrew von Eschenbach, Project FDA is a Manhattan Institute initiative that aims to help the FDA develop the tools it needs to meet 21st century challenges.

Date: Monday August 25, 2:00 - 4:45 p.m. ET
Panel participants and schedule: http://www.manhattan-institute.org/events/mi-08-25-14.htm
Location: Tufts University School of Medicine, Jaharis Family Center, 150 Harrison Avenue, Room 150, Boston, MA 02111

Read the full story at http://www.prweb.com/releases/2014/08/prweb12115968.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Lancet Neurology: Post-concussion return to play decision for footballers should be made solely by doctors, says new editorial
2. Parents want e-mail consults with doctors, but dont want to pay for them
3. Online USA Doctors, Virtual Doctor Create a New Approach to Help Those with Diabetes
4. Online USA Doctors, Virtual Doctors Present a New, Innovative Way of Treating Anxiety Disorder
5. Leading Edge Telemedicine Company SecondOpinions.com Provides Solution to Obamacare Challenges for Doctors, Patients and Insurance Industry
6. Leading Edge Telemedicine Company SecondOpinions.com Provides Solution to Obamacare Challenges for Doctors, Patients and Insurance Industry
7. Federal Laws Debut this Week to Expose Financial Ties Between Medical Companies and Doctors, Parker Waichman LLP Notes
8. Informatics approach helps doctors, patients make sense of genome data
9. Stanford-StartX Fund-Backed Nirmidas Biotech Raises $2 Million for Diagnostic Research Tools
10. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal
11. KRS Global Biotechnology, Inc. Announces the Compounded Service of Nitroglycerin.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Many RNA ... regulatory principles, the research team developed expressRNA, a web platform encompassing computational tools ... reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind to ...
(Date:6/20/2017)... ... 2017 , ... Uniform Advantage (UA), a multi-channel retailer of medical ... create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant and ... With trendy looks hitting the medical community, UA Flex is for the medical professional ...
(Date:6/20/2017)... ... June 20, 2017 , ... BrightStar Care Centerville/South Dayton, a ... the Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs ... a symbol of quality that reflects an organization’s commitment to meeting certain performance ...
(Date:6/20/2017)... ... 20, 2017 , ... Uniworld Boutique River Cruise Collection recently gave ... boutique ship, S.S. Joie de Vivre . What really sets this ship apart ... River and designed small enough to dock directly in Paris. With The Cruise Web’s ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
(Date:6/8/2017)... MCKINNEY, Texas , June 8, 2017 ... Company"), a leading developer and manufacturer of ... industry, announced today that Cressey & Company ... investment firm, has completed a growth-focused investment ... acquired a majority ownership position from selling ...
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
Breaking Medicine Technology: